A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
121actual
Sites
20
Country
Italy
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-26 | actual | When the study began enrolling |
| Primary completion | 2026-05-31 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-31 | actual | The whole study's end, after follow-up |
| First posted | 2023-02-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Relapse Multiple Myeloma
- Refractory Multiple Myeloma
Primary outcomes
what the primary-completion date above is the date OFReal-World Overall Response Rate (ORR) for each TCR MM therapy
measured 3-18 months
Real-World Progression Free Survival (PFS)
measured 3-18 months
Real-World Overall Survival (OS)
measured 3-18 months
Real-World Duration of response (DOR)
measured 3-18 months
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed